Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It acts via cranial vessel vasoconstriction and inhibition of neuropeptide release.
## Primary Indications
Acute treatment of migraine attacks with or without aura in adults and pediatric patients (6–17 years).
## Adult Dosing
* **Standard dose:** 5 mg or 10 mg orally.
* **Administration:** May repeat dose after 2 hours if migraine persists.
* **Maximum:** 30 mg in a 24-hour period.
* **Note:** Orally disintegrating tablets (ODT) should be placed on the tongue and allowed to dissolve; no water is required.
## Pediatric Dosing
* **Weight < 40 kg:** 5 mg orally.
* **Weight ≥ 40 kg:** 10 mg orally.
* **Administration:** May repeat dose once after 2 hours if necessary.
* **Maximum:** 10 mg in a 24-hour period (for weight < 40 kg) or 20 mg (for weight ≥ 40 kg).
## Dose Adjustments
* **Patients taking Propranolol:** Limit dose to 5 mg; maximum 15 mg in 24 hours due to increased rizatriptan plasma concentrations.
* **Renal/Hepatic Impairment:** Use with caution. Consider initial 5 mg dose in patients with moderate hepatic or renal impairment; clinical data is limited.
## Contraindications
* History of ischemic heart disease or coronary artery vasospasm (Prinzmetal’s angina).
* History of stroke or transient ischemic attack (TIA).
* Peripheral vascular disease.
* Ischemic bowel disease.
* Uncontrolled hypertension.
* Administration within 24 hours of another 5-HT1 agonist or ergotamine-type medication.
* Administration within 2 weeks of MAO inhibitor therapy.
## Adverse Effects
* **Common:** Dizziness, somnolence, paresthesia, fatigue, and dry mouth.
* **Serious:** Coronary vasospasm/myocardial ischemia, serotonin syndrome (when used with other serotonergic agents), and increased blood pressure.
## Key Drug Interactions
* **Propranolol:** Increases rizatriptan AUC; requires dose reduction as noted above.
* **MAO Inhibitors:** Risk of serotonin syndrome and increased rizatriptan exposure; absolute contraindication.
* **SSRIs/SNRIs:** Potential risk of serotonin syndrome; monitor for symptoms (agitation, tremor, hyperreflexia).
* **Ergot derivatives:** Do not administer within 24 hours of rizatriptan to avoid additive vasospastic effects.
## Monitoring
* Monitor cardiovascular status in patients with risk factors for coronary artery disease (e.g., postmenopausal women, men >40, diabetics).
* Monitor for signs of serotonin syndrome if combined with other agents affecting serotonin levels.
## Clinical Pearls
* Efficacy is highest when administered at the first onset of migraine.
* Rizatriptan ODT is not a "fast-acting" formulation compared to conventional tablets regarding peak plasma concentration; it offers convenience over efficacy speed.
* Frequent use (>10 days/month) can lead to medication overuse headache (MOH).
* Patients should be counseled that transient chest/throat tightness is a common sensory side effect not always indicative of cardiac ischemia, but cardiac evaluation is required if symptoms are severe or persistent.
***
**Disclaimer:** This information is for educational purposes only. Clinical protocols may vary by institution. Always verify specific dosing, safety requirements, and contraindications by consulting the current FDA-approved product labeling or institutional guidelines before prescribing or administering medication.
